SOX2作为宫颈癌的预后标志物和潜在分子靶点：一项荟萃分析。

SOX2 as a prognostic marker and a potential molecular target in cervical cancer: A meta-analysis.

作者信息

Yuan Dandan, Wang Jian, Yan Mingyu, Xu Yaohui

机构信息

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, PR China.

Inner Mongolia Medical College Third Affiliated Hospital, Baotou, PR China.

出版信息

Int J Biol Markers. 2021 Dec;36(4):45-53. doi: 10.1177/17246008211042899. Epub 2021 Oct 30.

DOI:10.1177/17246008211042899

PMID:34719977

Abstract

BACKGROUND

Sex determining region Y-box 2 (SOX2) has been reported as a potential therapeutic target for cancer. However, the role of SOX2 in cervical cancer remains largely undetermined. This study was performed to evaluate the correlation of SOX2 with clinical characteristics and prognosis in cervical cancer.

METHODS

Multiple databases were systematically searched for eligible publications. The combined odds ratios (ORs) or hazard ratios (HRs) with the corresponding 95% confidence intervals (CIs) were used to assess the effect sizes.

RESULTS

A total of 17 studies with 1906 participants were identified. SOX2 expression was higher in cervical cancer than in the normal control group (OR = 10.83, 95% CI = 6.64-17.67, < 0.001), while no significant difference was observed between cervical cancer and cervical intraepithelial neoplasia. SOX2 expression was not associated with age, tumor stage, and lymph node metastasis, but was correlated with tumor grade (grade 2-3 vs. grade 1: OR = 4.59, 95% CI = 2.76-7.62, < 0.001) and tumor size (≥4 cm vs. ≤4 cm: OR = 1.66, 95% CI = 1.05-2.60, = 0.028). Based on multivariate Cox analysis, SOX2 expression was not correlated with overall survival, but was closely associated with poor recurrence-free survival (HR = 5.83, 95% CI = 1.35-25.16, = 0.018) and progress-free survival HR = 2.29, 95% CI = 1.01-5.19, = 0.046).

CONCLUSION

SOX2 may serve as a novel prognostic factor and a promising molecular target for cervical cancer.

摘要

背景

性别决定区Y盒2（SOX2）已被报道为癌症的潜在治疗靶点。然而，SOX2在宫颈癌中的作用仍 largely未确定。本研究旨在评估SOX2与宫颈癌临床特征及预后的相关性。

方法

系统检索多个数据库以获取符合条件的出版物。采用合并比值比（OR）或风险比（HR）及相应的95%置信区间（CI）来评估效应大小。

结果

共纳入17项研究，1906名参与者。宫颈癌中SOX2表达高于正常对照组（OR = 10.83，95%CI = 6.64 - 17.67，< 0.001），而宫颈癌与宫颈上皮内瘤变之间未观察到显著差异。SOX2表达与年龄、肿瘤分期及淋巴结转移无关，但与肿瘤分级（2 - 3级 vs. 1级：OR = 4.59，95%CI = 2.76 - 7.62，< 0.001）和肿瘤大小（≥4 cm vs. ≤4 cm：OR = 1.66，95%CI = 1.05 - 2.60，= 0.028）相关。基于多因素Cox分析，SOX2表达与总生存期无关，但与无复发生存期差（HR = 5.83，95%CI = 1.35 - 25.16，= 0.018）和无进展生存期（HR = 2.29，95%CI = 1.01 - 5.19，= 0.046）密切相关。